Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | TG-1801 |
Trade Name | |
Synonyms | NI-1701|TG1801|TG 1801 |
Drug Descriptions |
TG-1801 (NI-1701) is a bispecific antibody that binds to CD47 and CD19 on B cells and blocks CD47 downstream signaling and subsequent activation of the SIRPa receptor on macrophages, potentially leading increased antitumor immune response and phagocytosis of tumor cells (PMID: 29743205, PMID: 35538512). |
DrugClasses | CD19 Antibody 21 CD47 Antibody 31 Immune Checkpoint Inhibitor 149 |
CAS Registry Number | NA |
NCIT ID | C166137 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
TG-1801 | TG-1801 | 0 | 2 |
TG-1801 + Ublituximab | TG-1801 Ublituximab | 0 | 2 |